Oncogenic alterations in papillary thyroid cancers of young patients

Thyroid

Volumn 22, Issue 1, 2012, Pages 17-26

  Sassolas, Geneviève ^a   Hafdi Nejjari, Zakia ^a   Ferraro, Angelo ^b   Decaussin Petrucci, Myriam ^c   Rousset, Bernard ^a   Borson Chazot, Françoise ^a,b,c,d   Borbone, Eleonora ^e   Berger, Nicole ^c   Fusco, Alfredo ^e  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; IODINE 131; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN NTRK; PROTEIN PATCHED 1; PROTEIN PTC 3; PROTEIN RET; RAS PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CANCER RECURRENCE; CHILD; DISTANT METASTASIS; ECTOPIC THYROID GLAND; FEMALE; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SIGNAL TRANSDUCTION; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; AGE FACTORS; CARCINOMA, PAPILLARY; CHILD; FEMALE; GENES, RAS; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84855426419     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0215     Document Type: Article

References (37)

1. Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, Thompson GB 2010 Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J Surg 34:1192-1202.
2. Schlumberger M, De Vathaire F, Travagli JP, Vassal G, Lemerle J, Parmentier C, Tubiana M 1987 Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab 65:1088-1094. (Pubitemid 18026839)
3. Sassolas G, Hafdi-Nejjari Z, Remontet L, Bossard N, Belot A, Berger-Dutrieux N, Decaussin-Petrucci M, Bournaud C, Peix JL, Orgiazzi J, Borson-Chazot F 2009 Thyroid cancer is the incidence rise abating? Eur J Endocrinol 160:71-79.
4. Nikiforov YE 2008 Thyroid carcinoma: molecular pathways and therapeutic targets. Mol Pathol 21:S37-S43. (Pubitemid 351592770)
5. Santoro M, Melillo RM, Fusco A 2006 RET/PTC activation in papillary thyroid carcinoma. Eur J Endocrinol 155:645-653.
6. Xing M 2007 BRAF mutation in papillary thyroid: cancer: pathogenetic role, molecular bases, and clinical implications. Endocr Rev 28:742-762. (Pubitemid 350294294)
7. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M, Nikiforov YE 2006 Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 91:3603-3610. (Pubitemid 44402144)
8. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE 2006 Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216-222. (Pubitemid 43740191)
9. Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, Ab A, Guiu XM, Sobrinho-Simoes M 2004 BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 202:247-251. (Pubitemid 38208663)
10. Basolo F, Giannini R, Monaco C, Melillo RM, Carlomagno F, Pancrazi M, Salvatore G, Chiappetta G, Pacini F, Elisei R, Miccoli P, Pinchera A, Fusco A, Santoro M 2002 Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am J Pathol 160:247-254. (Pubitemid 34052285)
11. Fenton CL, Lukes Y, Nicholson D, Dinauer C, Francis GL, Tuttle RM 2000 The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab 85:1170-1175. (Pubitemid 32269367)
12. Bongarzone I, Fugazzola L, Vigneri P, Mariani L, Mondellini P, Pacini F, Basolo F, Pinchera A, Pilotti S, Pierotti MA 1996 Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab 81:2006-2009. (Pubitemid 26152500)
13. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA 1997 Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57:1690-1694. (Pubitemid 27199660)
14. Bounacer A, Wicker R, Caillou B, Cailleux AF, Sarasin A, Schlumberger M, Suárez HG 1997 High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 15:1263-1273. (Pubitemid 27429741)
15. Penko K, Livezey J, Fenton C, Patel A, Nicholson D, Flora M, Oakley K, Tuttle RM, Francis G 2005 BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 15:320-325. (Pubitemid 40677402)
16. Rosenbaum E, Hosler G, Zahurak M, Cohen Y, Sidransky D, Westra WH 2005 Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Mod Pathol 18:898-902. (Pubitemid 41059949)
17. Kumagai A, Namba H, Saenko VA, Ashizawa K, Ohtsuru A, Ito M, Ishikawa N, Sugino K, Ito K, Jeremiah S, Thomas GA, Bogdanova TI, Tronko MD, Nagayasu T, Shibata Y, Yamashita S 2004 Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 89:4280-4284. (Pubitemid 39244426)
18. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404. (Pubitemid 37452745)
19. Puxeddu E, Moretti S, Elisei R, Romei T, Pascucci R, Martinelli M, Mario C, Avenia N, Rossi ED, Fadda G, Gavilliere A, Ribacchu R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F 2004 BRAF V599 E mutation is the leading genetic event in adult sporadic papillary thyroid carcinoma. J Clin Endocrinol Metab 89:2414-2420. (Pubitemid 38619884)
20. Fenton C, Anderson J, Lukes Y, Dinauer CA, Tuttle RM, Francis GL 1999 Ras mutations are uncommon in sporadic thyroid cancer in children and young adults. J Endocrinol Invest 22:781-789.
21. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE 2003 Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of RAS mutations. Am J Clin Pathol 120:71-77. (Pubitemid 37046372)
22. Brzeziańska E, Pastuszak-Lewandoska D, Lewinski A 2007 Rearrangements of NTRK1 oncogene in papillary thyroid carcinoma. Neuro Endocrinol Lett 28:221-229. (Pubitemid 47045763)
23. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627. (Pubitemid 36553510)
24. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379. (Pubitemid 41759286)
25. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R 2006 Correlation between B-RAF V600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13:455-464. (Pubitemid 43886668)
26. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F 2008 BRAF (V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93:3943-3949.
27. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyl M, Janakiraman M, Solit D, Knauf JA, Tuttle M, Ghossein RA, Fagin JA 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3- CA, and AKT1. Cancer Res 69:4885-4893.
28. Borson-Chazot F, Bardet S, Bournaud C, Conte-Devolx B, Corone C, D'Herbomez M, Henry JF, Leenhardt L, Peix JL, Schlumberger M, Wemeau JL; Expert Group for French Recommendations for the Management of Differentiated Thyroid Carcinomas of Vesicular Origin, Baudin E, Berger N, Bernard MH, Calzada-Nocaudie M, Caron P, Catargi B, Chabrier G, Charrie A, Franc B, Hartl D, Helal B, Kerlan V, Kraimps JL, Leboulleux S, Le Clech G, Menegaux F, Orgiazzi J, Perié S, Raingeard I, Rodien P, Rohmer V, Sadoul JL, Schwartz C, Tenenbaum F, Toubert ME, Tramalloni J, Travagli JP, Vaudrey C 2008 Guidelines for the management of differentiated thyroid carcinomas of vesicular origin. Ann Endocrinol (Paris) 69:472-486.
29. Sobin LH 2009 TNM Classification of Malignant Tumours, 7th edition. Wiley-Blackwell.
30. Caudill CM, Zhu Z, Ciampi R, Stringer JR, Nikiforov YE 2005 Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocrinol Metab 90:2364-2369. (Pubitemid 40586286)
31. Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, Decaussin M, Peix JL, Bournaud C, Orgiazzi J, Borson-Chazot F, Dante R, Rousset B 2005 Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classic papillary thyroid carcinomas. J Clin Endocrinol Metab 90:3028-3035. (Pubitemid 40686360)
32. Liu J, Singh B, Tallini G, Carlson DL, Katabi N, Shaha A, Tuttle RM, Ghossein RA 2006 Follicular variant of papillary thyroid carcinoma Cancer 107:1255-1264.
33. Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA 2010 Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23:1191-1200.
34. Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, Zhang Y, Cheng W, Zhao W 2009 Analysis of differential BRAF (V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 16:240-245.
35. Moses W, Weng J, Khanafshar E, Duh QY, Clark OH, Kebebew E 2010 Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation. J Surg Res 160:179-183.
36. Borson-Chazot F, Causeret S, Lifante JC, Augros M, Berger N, Peix JL 2005 Predictive factors for recurrence from a series of 74 children and adolescents with differentiated thyroid cancer. World J Surg 28:1088-1092.
37. Durand S, Ferraro-Peyret C, Joufre M, Chave A, Borson- Chazot F, Selmi-Ruby S, Rousset B 2009 Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features. Endocr Relat Cancer 16: 467-481.